GI Innovation stock soars as bequest payment surpasses target, reaching 온라인 바카라 사이트 111.2 billion

[by Lee, Young Sung] GI Innovation successfully raised a total of 온라인 바카라 사이트 111.2 billion (approximately USD 75.5 million) through a paid-in capital increase, reflecting the expectations in the capital market by far surpassing its initial target of 온라인 바카라 사이트 80 billion without issuing any real rights shares. The soaring increase in capital was driven by the continuous rise in the issuance price, which surged by 68% following the announcement of the paid-in capital increase.

GI Innovation recently revealed in a public disclosure that it successfully issued 11,644,800 registered common shares, raising a total of 온라인 바카라 사이트 111.2784 billion. The capital increase was executed through a general public offering of real rights shares, following allocation to shareholders. The full (100%) payment for the offering was completed on March 27, approximately three months after the board of directors' resolution on December 20, 2024. The new shares are set to be listed on April 10.

The company initially set a target of 온라인 바카라 사이트 80 billion (approximately USD 54.4 million) for its capital increase. However, due to a surge in stock price and strong investment demand, GI Innovation successfully secured an additional 온라인 바카라 사이트 30 billion beyond its original goal. This reflects the market's optimistic outlook on the company's pipeline and growth potential. Notably, CSO Jang Myoung-ho, the company’s founder and the largest shareholder, subscribed to 50% of the allocated shares.

On December 2024, when the decision to proceed with the capital increase was first announced, GI Innovation's stock price (based on the closing price) stood at 온라인 바카라 사이트 9,220. By March 14 of this year, when the final issuance price for the new shares was confirmed, the stock had surged by 68% to 온라인 바카라 사이트 15,530. This increase in stock value was accompanied by a corresponding rise in the issue price. Initially set at 온라인 바카라 사이트 6,870, a 25% discount, the issue price was later finalized at 온라인 바카라 사이트 8,400 for the first issuance and 온라인 바카라 사이트 9,550 for the subsequent offering.

The company intends to allocate the raised funds to several initiatives, including the Phase 1 and 2 clinical trials in Korea and the United States for its immunotherapy candidates 'GI-101A' and 'GI-102', the clinical trials for the metabolic anticancer candidate 'GI-108,' the R&D of new pipeline candidates like GI-305, GI-213, and GI-128, and general operating expenses.